CA
NZ
UK
AU
IND
US
Biomea Fusion, Inc. (NASDAQ:BMEA) shares rose in pre-market trading after the company announced completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II trial evaluating its lead candidate icovamenib in patients with insulin-deficient type 2 diabetes who remain inadequately controlled on standard-of-care therapies.
Caris Life Sciences, Inc. (NASDAQ:CAI) shares pulled back modestly in pre-market trading, giving back a small portion of a powerful multi-week rally that has taken the stock roughly 65% to 73% higher off its May lows. The pullback follows an August 5 earnings report …
GeoVax Labs, Inc. (NASDAQ:GOVX) shares rose in pre-market trading ahead of Chairman, President and Chief Executive Officer David Dodd's participation in the 2026 Georgia Life Sciences Summit, scheduled for August 25 and 26 in Sandy Springs, Georgia. Dodd, a former chair of Georgia Life …
Kairos Pharma, Ltd. (NYSE American:KAPA) shares fell in pre-market trading ahead of the company's previously announced 1-for-7 reverse stock split, which is set to become effective at 12:01 a.m. Eastern Time on September 1, 2026. Shares are expected to begin trading on a split-adjusted …
LifeVantage Corporation (NASDAQ:LFVN) shares fell in pre-market trading ahead of the company's fiscal fourth-quarter and full fiscal year 2026 results, scheduled for release after the market closes on Thursday, August 27, with a conference call to follow the same afternoon. The pre-market move comes …
908 Devices Inc. (NASDAQ:MASS) shares rose in pre-market trading, extending recent momentum ahead of the company's scheduled presentation at the 17th Annual Midwest IDEAS Investor Conference on August 26. Chief Executive Officer and Co-founder Kevin J. Knopp and Chief Financial Officer Joe Griffith are …
AEON Biopharma, Inc. (NYSE American:AEON) shares rose in pre-market trading after the company announced final, expanded primary structure results supporting the molecular similarity of its lead candidate ABP-450 to BOTOX. The expanded analysis achieved 98% sequence coverage of the active botulinum neurotoxin, up from …
• Shares trading up 4.01% pre-market, adding $1.15 to reach $29.82, extending Friday's 7.90% regular-session gain
• Shares trading up 4.55% pre-market, adding $0.60 to reach $13.68, after closing essentially flat in Friday's regular session
• Shares trading up 45.17% pre-market, adding $1.45 to reach $4.66, extending Friday's 5.94% regular-session gain
Please wait processing your request...